La vendita allo scoperto per Myomo dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Myomo. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Myomo (AMEX:MYO) Azioni, Report sulle vendite allo scoperto

MYOMO INC

Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Myomo Inc

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and lowers the price target from $87 to $75.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Masco, Lowers Price Target to $75

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension&nbsp;(OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (gMG)</a>.
Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)&nbsp;and QMG (quantifies disease severity)&nbsp;scores over 84 weeks with sustained reductions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678645/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-t" rel="noreferrer noopener">in total immunoglobulin G (IgG)</a>.
Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p&lt;0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p&lt;0.001) mean change&nbsp;for study participants who transitioned from placebo and SOC to nipocalimab and SOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651117/johnson-johnsons-tremfya-shows-efficacy-across-multiple-domains-in-late-stage-psoriatic-arthritis-study" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study</a>
In the antibody-positive population, 45%&nbsp;of patients receiving steroids at the OLE baseline were able to decrease or discontinue steroids at the time of this data cut by more than half of the baseline dose.
<ul>
<li>Among these patients, the mean dose of prednisone decreased from 23 to 10&nbsp;mg daily.</li>
</ul>
Nipocalimab had a consistent and tolerable safety profile throughout the OLE phase.
Additional findings from the Phase 3 Vivacity-MG3 study indicate that patients treated with nipocalimab plus SOC achieved statistically significant improvements in their QMG score by -4.9 versus placebo plus SOC (p&lt;0.001) over weeks 22 and 24.
Patients in the nipocalimab plus SOC treatment group were four times more likely to sustain symptom improvement at 20 weeks than the placebo plus SOC group, as measured by a three- or greater-point improvement on the QMG score.
Results show significantly more patients treated with nipocalimab (36.4%) versus placebo (10.5%, p&lt;0.001) spent greater than 75% of the study duration, demonstrating improvements in the QMG score.
A reduction of more than three points in the QMG score indicates a decrease in the severity of the patient&#8217;s symptoms due to improvements in muscle strength, allowing patients to carry out important daily activities such as swallowing and chewing.
Price Action: JNJ stock is down 0.21% at $150.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" target="_blank" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

Health Care

General

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Barclays analyst Matthew Bouley maintains Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a Equal-Weight and lowers the price target from $7 to $6.

LSEA

Barclays Maintains Equal-Weight on Landsea Homes, Lowers Price Target to $6

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $6 to $5.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $5

Macro Economic Events

Politics

Global

Economics

Canada Says It's Already Announced 25% Counter-tariffs Against Some US-Made Autos, Will Go Into Effect April 9; Says The Tariffs Will Remain In Place Until U.S. Eliminates Its Tariffs Against The Canadian Auto Sector- Reuters

Barclays analyst Matthew Bouley maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Equal-Weight and lowers the price target from $11 to $8.

HLMN

Barclays Maintains Equal-Weight on Hillman Solns, Lowers Price Target to $8

Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (MG)</a>.
MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction.
As&nbsp;previously announced, the trial met its primary endpoint and demonstrated a safety profile supporting outpatient <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39594800/cartesians-autoimmune-disorder-candidate-hits-primary-goal-in-mid-stage-study-announces-equity-ra" rel="noreferrer noopener">administration of Descartes-08</a>.
As of a March 31, 2025, cutoff date, 12 out of 15 participants who received Descartes-08 in the primary efficacy dataset completed <a href="https://www.benzinga.com/pressreleases/25/04/g44681067/cartesian-therapeutics-descartes-08-observed-to-provide-deep-and-sustained-benefits-through-month-" target="_blank" rel="noreferrer noopener">their Month 12 follow-up assessments</a>.
Participants treated with Descartes-08 were observed to have deep responses following initial treatment and sustained symptom improvement, with an average MG Activities of Daily Living (MG-ADL, score to assess impact on daily functions) reduction of 5.5 (±1.1) at Month 4 and 4.8 (±1.4) at Month 12.
<ul>
<li>Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0±2.1).</li>
<li>33% (4/12) of participants achieved minimum symptom expression (MSE), defined as an MG-ADL score of 0 or 1, at month 6, all of whom maintained MSE through month 12.</li>
<li>83% (10/12) of evaluable participants maintained a clinically meaningful response through month 12.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44694287/pacira-settles-patent-dispute-over-exparel-with-fresenius-and-others-delays-pain-med-exparels-generics-entry-until-2030-stock-jumps" rel="noreferrer noopener">Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med&#8217; Generics Entry Until 2030, Stock Jumps</a>
The subset of participants who had not been exposed to prior biologic therapies exhibited a deepening of responses throughout the year, with an average MG-ADL reduction of 6.6 (±1.5) at Month 4 and 7.1 (±1.9) at month 12.
<ul>
<li>The participants were observed to have an average QMG reduction of 5.9 (±2.4) points at month 4, which deepened through month 12 (9.4±2.6).</li>
<li>57% (4/7) of these participants were observed to achieve MSE at month 6, which was maintained through month 12.</li>
<li>100% (7/7) of these participants were observed to maintain at least a clinically meaningful response through month 12.</li>
</ul>
Consistent with previously reported data, Descartes-08 was observed to be well-tolerated across the safety dataset through month 12 (n=12), and adverse events were transient and mostly mild, with no new adverse events reported in the 12-month follow-up data.
Cartesian remains on track to commence the Phase 3 AURORA trial of Descartes-08 in MG in the second quarter of 2025.
RNAC Price Action: Cartesian Therapeutics stock is down 3.56% at $9.75 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44691525/wd-40-margins-expand-in-q2-raises-2025-profit-outlook" target="_blank" rel="noreferrer noopener">WD-40 Margins Expand In Q2, Raises 2025 Profit Outlook</a></li>
</ul>
Photo: Shutterstock

RNAC

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients

Barclays analyst Matthew Bouley maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Overweight and lowers the price target from $79 to $68.

FBIN

Barclays Maintains Overweight on Fortune Brands, Lowers Price Target to $68

Barclays analyst Matthew Bouley maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Equal-Weight and lowers the price target from $145 to $120.

Barclays Maintains Equal-Weight on D.R. Horton, Lowers Price Target to $120

Barclays analyst Matthew Bouley maintains Champion Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) with a Equal-Weight and lowers the price target from $106 to $97.

Barclays Maintains Equal-Weight on Champion Homes, Lowers Price Target to $97

CORRECTION: Retail Stocks Are Lower

Argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">favorable safety profile</a>.
ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart&#8217;s bi-weekly and every <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44677982/argenx-highlights-vyvgart-data-at-aan-2025-setting-new-standard-in-sustained-efficacy-and-improved" rel="noreferrer noopener">three-week dosing schedules</a>.
<ul>
<li>Over the course of the study (126 weeks), 75% of patients showed sustained efficacy, achieving 2 points or more of improvement in MG activities of daily living (MG-ADL score) during more than 75% of study visits.</li>
<li>In addition, more than half (56.5%) of participants achieved minimal symptom expression (MSE) during the study.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42538247/analysts-optimistic-on-biohavens-bhv-1300-ahead-of-2025-catalysts" rel="noreferrer noopener">Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval</a>
Interim results of ADAPT-SC+ demonstrate consistent and repeatable improvements in MG-ADL (functional score) and MG Quality of Life (MG-QoL) scores in gMG patients treated with Vyvgart Hytrulo.
There was no observed increase in infections or injection-site reactions over nine treatment cycles. Also, the proportion of patients achieving MSE was consistent across multiple cycles.
ADHERE+ data demonstrated Vyvgart Hytrulo delivers long-term clinical efficacy.
The study showed functional improvements across aINCAT disability scores (&gt;1-point), grip strength (&gt;17 kPa), and the I-RODS scale (&gt;8 points) at week 36 compared to baseline at entry to the standard of care withdrawal phase.
In addition, the majority of ADHERE patients who relapsed during randomized treatment withdrawal stage, restabilized on Vyvgart – 50% as early as week 4.
Argenx is pursuing label extension for Vyvgart, including through two Phase 3 studies for seronegative gMG (ADAPT-SERON) and ocular MG (ADAPT-OCULUS).
Price Action: ARGX stock is up 3.05% at $566.76 at the last check on Tuesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44694920/trump-administration-reverses-bidens-plan-for-medicare-coverage-of-obesity-drugs-like-ozempic-and-zepbound" target="_blank" rel="noreferrer noopener">Trump Administration Reverses Biden&#8217;s Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound</a></li>
</ul>

Movers

ARGX

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

ANF, COLM, CPRI, GAP, GES, HBI, HELE, LULU, PVH, UA, UAA, W, XRT

WIIM

COLM

CPRI

HELE

LULU

Shares of retail and apparel stocks are trading lower as investors weigh the potential impacts of tariffs on the sector. Economic uncertainty could also cloud consumer spending outlook.

Whales with a lot of money to spend have taken a noticeably bullish stance on Palantir Technologies.
Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 31 trades.
If we consider the specifics of each trade, it is accurate to state that 48% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $347,038 and 24, calls, for a total amount of $1,846,334.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $150.0 for Palantir Technologies over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palantir Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palantir Technologies's whale activity within a strike price range from $55.0 to $150.0 in the last 30 days. 
<h3>Palantir Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136225_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$21.5</td>
<td>$21.3</td>
<td>$21.5</td>
<td>$115.00</td>
<td>$632.1K</td>
<td>1.2K</td>
<td>863</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$4.1</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$84.00</td>
<td>$199.3K</td>
<td>2.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$19.25</td>
<td>$18.8</td>
<td>$19.05</td>
<td>$100.00</td>
<td>$112.6K</td>
<td>3.6K</td>
<td>462</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.05</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$90.00</td>
<td>$84.0K</td>
<td>14.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.42</td>
<td>$80.00</td>
<td>$69.0K</td>
<td>4.7K</td>
<td>301</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
Having examined the options trading patterns of Palantir Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Palantir Technologies Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 97,926,469, with PLTR's price up by 3.24%, positioned at $80.36.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Palantir Technologies</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $125.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Palantir Technologies, targeting a price of $125. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Palantir Technologies with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

PLTR

Smart Money Is Betting Big In PLTR Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Alibaba Gr Hldgs.
Looking at options history for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) we detected 37 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 45% with bearish.
From the overall spotted trades, 21 are puts, for a total amount of $2,313,864 and 16, calls, for a total amount of $1,326,013.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $82.5 to $200.0 for Alibaba Gr Hldgs over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Alibaba Gr Hldgs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alibaba Gr Hldgs's whale trades within a strike price range from $82.5 to $200.0 in the last 30 days. 
<h3>Alibaba Gr Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136219_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$10.45</td>
<td>$9.9</td>
<td>$10.1</td>
<td>$105.00</td>
<td>$353.5K</td>
<td>3.0K</td>
<td align="right">600</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.15</td>
<td>$10.9</td>
<td>$11.0</td>
<td>$105.00</td>
<td>$330.0K</td>
<td>20.2K</td>
<td align="right">480</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.7</td>
<td>$10.15</td>
<td>$10.3</td>
<td>$100.00</td>
<td>$309.0K</td>
<td>5.4K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.55</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$82.50</td>
<td>$252.7K</td>
<td>95</td>
<td align="right">245</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$25.5</td>
<td>$24.5</td>
<td>$24.9</td>
<td>$110.00</td>
<td>$249.0K</td>
<td>2.6K</td>
<td align="right">600</td>
</tr>
</tbody>
</table>

<h3>About Alibaba Gr Hldgs</h3>
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
<h3>Alibaba Gr Hldgs's Current Market Status</h3>
<ul>
<li>Trading volume stands at 35,174,347, with BABA's price down by -5.65%, positioned at $99.99.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Alibaba Gr Hldgs</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $170.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Alibaba Gr Hldgs, targeting a price of $170. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alibaba Gr Hldgs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

BABA

A Closer Look at Alibaba Gr Hldgs's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SMCI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Super Micro Computer.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 53%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $360,476, and 10 are calls, for a total amount of $562,458.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $50.0 for Super Micro Computer, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Super Micro Computer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Super Micro Computer's whale trades within a strike price range from $3.0 to $50.0 in the last 30 days. 
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744136214_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.2</td>
<td>$40.00</td>
<td>$162.3K</td>
<td>2.8K</td>
<td align="right">203</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$7.3</td>
<td>$7.15</td>
<td>$7.3</td>
<td>$35.00</td>
<td>$116.8K</td>
<td>1.9K</td>
<td align="right">22</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.75</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$35.00</td>
<td>$88.6K</td>
<td>3.5K</td>
<td align="right">101</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.55</td>
<td>$31.45</td>
<td>$32.32</td>
<td>$3.00</td>
<td>$77.5K</td>
<td>292</td>
<td align="right">0</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.85</td>
<td>$12.75</td>
<td>$12.85</td>
<td>$45.00</td>
<td>$57.8K</td>
<td>4.7K</td>
<td align="right">81</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, Big Data, high-performance computing, and the "Internet of Things" embedded markets. Its solutions include server, storage, blade, and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular, and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
<h3>Present Market Standing of Super Micro Computer</h3>
<ul>
<li>With a volume of 43,719,762, the price of SMCI is up 0.88% at $33.29. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About Super Micro Computer</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $52.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Rosenblatt has revised its rating downward to Buy, adjusting the price target to $60. 
&#x2A; In a positive move, an analyst from JP Morgan has upgraded their rating to Neutral and adjusted the price target to $45. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

SMCI

Check Out What Whales Are Doing With SMCI

On Friday, China&#8217;s finance ministry announced a 34%&nbsp;tariff on all goods imported&nbsp;from the U.S., effective April 10, in response to the U.S. administration&#8217;s 54% duties imposed by the Trump-led administration during the so-called <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">Liberation Day last week</a>.
Trump has&nbsp;threatened to impose an additional 50% duty&nbsp;on Chinese imports if Beijing does not <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility" rel="noreferrer noopener">drop the 34% tariffs</a>.
On Monday, Trump hinted at more openness in trade negotiations with China after threatening to impose a 50% tariff on top of the 54% already levied.
&#8220;China also wants to make a deal badly, but they don&#8217;t know how to get it started,&#8221; <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44686417/wall-street-soars-as-trump-teases-trade-deals-magnificent-seven-add-over-500-billion-in-market-value" rel="noreferrer noopener">Trump wrote</a>.
Wedbush analyst Daniel Ives writes that &#8220;saying we can just make this in the USA&#8221; understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44686417/wall-street-soars-as-trump-teases-trade-deals-magnificent-seven-add-over-500-billion-in-market-value" rel="noreferrer noopener">Wall Street Soars As Trump Teases Trade Deals, Magnificent 7 Add Over $500 Billion In Market Value</a>
&#8220;The reason I believe this is the biggest debacle ever seen in the markets is because its purely self-inflicted by Trump, and the logic about &#8220;near-term pain&#8221; is being way miscalculated, which speaks to our concern. It&#8217;s very easy to say &#8220;build in America&#8221; behind a microphone in the Beltway&#8230;the reality is so much different it&#8217;s almost a scary concept,&#8221; says Daniel Ives.
For U.S. tech/auto companies, tariffs are like flipping a boat with no life rafts.
The list of vulnerable companies is long and includes Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), among others.
Building a factory in the U.S. takes four to five years. The analyst explains that high labor costs and other expenses in the U.S. don&#8217;t align with how modern supply chains are designed to operate. This makes it hard to compete with Chinese tech giants like BYD Co Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), Huawei, Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Tencent Holdings Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCTZF#OTC">TCTZF</a>)—and many others—a big opportunity to expand their global reach.
Also, much of the key technology and intellectual property behind these supply chains is already deeply rooted in Asia. So, any effort to shift production to the U.S. would take at least a decade to make a real impact, Wedbush analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696126/trump-administration-shuts-down-the-department-of-justices-crypto-crime-unit" target="_blank" rel="noreferrer noopener">Trump Administration Shuts Down The Department Of Justice&#8217;s Crypto Crime Unit</a></li>
</ul>
 Image: Shutterstock

Analyst Color

AAPL

BYDDF

BYDDY

MSFT

NVDA

TCEHY

TCTZF

Trump Tariff Strategy Creates 'Self-Inflicted Market Debacle': Analyst

Macro Notification

State Dept: Russian And U.S. Delegations Will Meet In Istanbul For A Second Time On April 10-Reuters

In a <a href="https://www.benzinga.com/topic/cryptocurrencies">crypto-linked</a> stock market that oscillates like a pendulum, Bitwise Asset Management introduced a plan to translate that volatility into money. The company has introduced <a href="https://www.benzinga.com/etfs">three new ETFs</a>, each targeting option income strategies based on some of the most volatile stocks in the crypto universe: Bitwise MSTR Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMST#NYSE">IMST</a>), Bitwise COIN Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICOI#NYSE">ICOI</a>) and the Bitwise MARA Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMRA#NYSE">IMRA</a>).
Each of these funds is structured on a covered call strategy intended to capture income by selling options on individual shares of MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>). The concept? Ride the turbulence in the market on your side. Receive premiums on selling options and maintain a long position to derive at least a partial benefit from any upside the stock yields.
Also Read: <a href="https://www.benzinga.com/real-estate/reit/25/04/44683691/lpre-etf-looks-past-reits-to-capture-greater-real-estate-economy">LPRE ETF Looks Past REITs To Capture &#8216;Greater&#8217; Real Estate Economy (CORRECTED)</a>
These are not passive, rules-based products. Rather, they&#8217;re operated with a hands-on mindset by Bitwise&#8217;s Head of Alpha Strategies, Jeff Park. &#8220;It's essential to be constantly monitoring news, capital flows, regulatory developments, options pricing, market sentiment, and other dynamics to most intelligently capitalize on this strategy. That's the approach we're taking with IMST, ICOI, and IMRA, and we hope to bring investors the combination of monthly income and strong, limited participation in equity gains as a result,&#8221; he said.
Park is accompanied by a group of co-managers—Jennifer Thornton, Daniela Padilla, and Gayatri Choudhury—who will guide these funds with daily active management, which is fairly uncommon in the ETF space.
The <a href="https://www.businesswire.com/news/home/20250403628192/en/Bitwise-Launches-Option-Income-ETF-Suite-a-Dynamic-Active-Approach-to-Covered-Calls-on-MSTR-COIN-and-MARA">objective </a>is clear: earn monthly returns for investors while sharing in some of the capital gain in these stocks. There&#8217;s a trade-off, naturally—selling calls limits the upside potential, but the ongoing premiums provide a predictable income stream, which is particularly attractive in volatile markets.
Bitwise CEO Hunter Horsley says crypto's volatility isn't just something to endure—it's something to harness.
Interestingly, these funds don&#8217;t actually own shares of MSTR, COIN or MARA. Rather, they employ synthetic exposure to mimic the stock positions. Pure equity players may want to look elsewhere, but for those who wish to combine crypto market themes with an income strategy, this launch may be the sweet spot.
Each fund has a 0.98% net expense fee, although IMST and ICOI are associated with a minor fee waiver that cuts the gross fee from 0.99% until March 2027.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44695765/crypto-etfs-sink-as-trump-tariffs-trigger-panic-this-could-reset-the-macro-narrative">Trump Tariffs Spark $800M Crypto ETF Rout: Can The Macro Narrative Shift?</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

COIN

Bitwise Funds Trust Bitwise COIN Option Income Strategy ETF

ICOI

IMRA

IMST

MARA

MSTR

Bitwise Turns Crypto Volatility Into Yield With New ETF Trio

Hedge fund manager Dan Loeb had five major financial stocks in the Third Point LLC portfolio, <a href="https://www.benzinga.com/topic/third-point-llc">each on the downtrend</a>. 
What Happened: Last week, shares of companies within the broader financials sector traded lower as markets reacted to President Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44678625/did-trump-team-manipulate-tariff-formula-to-achieve-higher-rates-experts-weigh-in-as-they-think-whole-thing-was-rigged" target="_blank" rel="noreferrer noopener">sweeping tariff announcement</a>.
Here&#8217;s a look at some of Loeb&#8217;s financial stocks year-to-date:
<ul>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): Shares dropped 33.54% compared to Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) decline of 17.85% YTD. As of the fourth quarter <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">of </a>2024, the investor lowered the stake to 400,000 shares from 950,000 shares as of the third quarter <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">of </a>2024.</li>
</ul>
<ul>
<li>Brookfield Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>): The stock dipped 20.59% vs its peer BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) that plummetted 19.92% YTD. Loeb raised the stake to 4,990,000 shares as of the fourth quarter of 2024 from 4,725,000 as of the third quarter of 2024.</li>
</ul>
<ul>
<li>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>): Shares were down 14.28% compared to Davis Fundamental ETF Trust Davis Select Financial ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DFNL#BATS">DFNL</a>), which saw a decrease of 9.68% YTD. Third Point acquired 925,000 shares in the fourth quarter of 2024.</li>
</ul>
<ul>
<li>LPL Financial Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>): The company&#8217;s shares tumbled 13.58% versus Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GABF#NYSE">GABF</a>) decrease of 15.99% YTD. The investor increased their stake to 655,000 shares in the fourth quarter of 2024 from 485,000 shares as of the third quarter of 2024.</li>
</ul>
<ul>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): The stock dived 14.30% compared to iShares Focused Value Factor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOVL#NYSE">FOVL</a>) decline of 12.16% YTD. Loeb acquired 640,000 shares in the company in the fourth quarter of 2024.</li>
</ul>
Why It Matters: U.S. banks and economists are now on recession watch.
JPMorgan analyst Maia G. Crook raised the U.S. recession risk to 60% from 40% last month, citing tariff hikes as the biggest U.S. tax<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy" target="_blank" rel="noreferrer noopener"> increase in decades</a>.
Last week, Trump argued it was necessary to address the U.S.'s <a href="https://www.benzinga.com/general/market-summary/25/04/44623604/us-stock-likely-to-open-lower-following-trumps-tariffs-worse-than-the-worst-case-scenario-says-analyst" target="_blank" rel="noreferrer noopener">&#8220;large and persistent trade deficit</a>,&#8221; adding: &#8220;Treat us like we treat you.&#8221;
The Trump administration proposed steep new tariffs on several countries, including 54% on China, 46% on Vietnam, 36% on Thailand, and 20% on the EU, while maintaining current rates for USMCA-<a href="https://www.benzinga.com/25/04/44589523/trumps-liberation-day-tariff-plan-could-ignite-global-trade-shakeup-betting-markets-price-in-the-pain" target="_blank" rel="noreferrer noopener">compliant goods from Mexico and Canada</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44496640/these-5-dan-loeb-portfolio-stocks-are-up-over-30-in-the-past-year" target="_blank" rel="noreferrer noopener">These 5 Dan Loeb Portfolio Stocks Are Up Over 30% In The Past Year</a></li>
</ul>
Image: Shutterstock

Mid Cap

DFNL

FDFF

FOVL

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GABF

LPLA

Tariffs Test Loeb's Financial Picks: Third Point Adjusts Bets As Markets Brace For Economic Blowback

Press Releases

Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit

Myomo to Report Third Quarter Financial Results on November 6, 2024

Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo, Inc. Announces Proposed Public Offering of Common Stock

Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Myomo to Report Fourth Quarter 2024 Financial Results on March 10

Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

Comments

Myomo

Vendite allo scoperto

Myomo (AMEX:MYO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO